-
Posted by
Two Blokes Jul 24 -
Filed in
Stock
-
5 views
AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised myasthenia gravis in adults.
